-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the rapid development of China's pharmaceutical and biotechnology industries, the amount of IPO financing in the industry has been increasing year by year
.
According to Refinitiv's data, there will be 19 Chinese biotech companies IPOs in 2020, mainly listed in Hong Kong, which have raised a total of US$5.
2 billion
.
In addition, according to incomplete statistics in the industry, IPO financing in the biotechnology industry has remained active since this year.
During the year, there were 20 Chinese biotechnology companies IPOs with a total financing of US$4.
6 billion
.
In addition, there are nearly 30 Chinese biotech companies in preparation for IPO
.
Judging from the biotechnology companies that have been listed on the Hong Kong Stock Exchange, since this year, more than half of the companies with IPO financing of more than 1 billion Hong Kong dollars, and there are many companies with more than 5 billion Hong Kong dollars
.
For example, Zhaoyan New Medicine officially landed on the Hong Kong Stock Exchange on February 26 this year, raising up to HK$6.
542 billion.
The capital raised was used for the construction of new facilities in Guangzhou and Chongqing, broadening the scope of comprehensive services in the drug R&D value chain, and expanding overseas Market, improve the service capabilities of Suzhou GLP facilities, strengthen American business to meet the increasing service needs of customers, daily operations, and expand comprehensive contract research organization services
.
The company is a private CRO company engaged in drug non-clinical evaluation and specializing in new drug pharmacology and toxicology research.
It focuses on non-clinical CRO business and has core advantages in drug safety evaluation.
At the same time, it is also expanding drug discovery, preclinical and clinical trials.
Phase of comprehensive drug research and development services
.
Hutchison Pharmaceuticals was listed in Hong Kong on June 30, 2021.
The funds raised through this issuance approached 5 billion Hong Kong dollars, or 4.
796 billion Hong Kong dollars.
The late-stage clinical plans of Nigeria, HMPL-689 and HMPL-523 to conduct registration trials and potential submission of NDA applications; support further proof-of-concept studies; enhance the company’s comprehensive strength in commercialization, clinical, regulatory and production; for the potential global business development and strategic acquisition opportunities to provide funds
.
The company is a global biomedical company in the commercialization stage, focusing on the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immune diseases
.
In addition, the listing of the unprofitable company Connoa Biotechnology has been favored by many capitals
.
On July 8, Connoa Bio was listed on the Hong Kong Stock Exchange, sponsored by Morgan Stanley, CICC, and Huatai International
.
Cornerstone investors, including Temasek, Hillhouse Capital, UBS and Invesco Asset Management (Singapore) Limited
.
The funds raised in this round amounted to HK$3.
571 billion, which will be used for the development and commercialization of key candidate pipelines
.
The company focuses on the development of innovative biological therapies in the field of autoimmunity and tumor immunotherapy
.
From the perspective of the industry, behind the continuous entry of capital is the strong rise of China's innovative biotechnology industry
.
In recent years, in the face of the growing domestic market, with the support of favorable policies and the increasing acceptance of innovative therapies in the country, a number of local biotechnology companies have risen rapidly, constantly developing innovative drugs, and are facing a huge scale.
, While focusing more and more on innovation in the domestic market, it also faces the international market
.
In this context, China's biotechnology has gradually attracted a wider range of strategic investors
.
However, the industry also pointed out that there are still parts to be solved and developed, including basic research and technology transfer, which need to be improved
.
.
According to Refinitiv's data, there will be 19 Chinese biotech companies IPOs in 2020, mainly listed in Hong Kong, which have raised a total of US$5.
2 billion
.
In addition, according to incomplete statistics in the industry, IPO financing in the biotechnology industry has remained active since this year.
During the year, there were 20 Chinese biotechnology companies IPOs with a total financing of US$4.
6 billion
.
In addition, there are nearly 30 Chinese biotech companies in preparation for IPO
.
Judging from the biotechnology companies that have been listed on the Hong Kong Stock Exchange, since this year, more than half of the companies with IPO financing of more than 1 billion Hong Kong dollars, and there are many companies with more than 5 billion Hong Kong dollars
.
For example, Zhaoyan New Medicine officially landed on the Hong Kong Stock Exchange on February 26 this year, raising up to HK$6.
542 billion.
The capital raised was used for the construction of new facilities in Guangzhou and Chongqing, broadening the scope of comprehensive services in the drug R&D value chain, and expanding overseas Market, improve the service capabilities of Suzhou GLP facilities, strengthen American business to meet the increasing service needs of customers, daily operations, and expand comprehensive contract research organization services
.
The company is a private CRO company engaged in drug non-clinical evaluation and specializing in new drug pharmacology and toxicology research.
It focuses on non-clinical CRO business and has core advantages in drug safety evaluation.
At the same time, it is also expanding drug discovery, preclinical and clinical trials.
Phase of comprehensive drug research and development services
.
Hutchison Pharmaceuticals was listed in Hong Kong on June 30, 2021.
The funds raised through this issuance approached 5 billion Hong Kong dollars, or 4.
796 billion Hong Kong dollars.
The late-stage clinical plans of Nigeria, HMPL-689 and HMPL-523 to conduct registration trials and potential submission of NDA applications; support further proof-of-concept studies; enhance the company’s comprehensive strength in commercialization, clinical, regulatory and production; for the potential global business development and strategic acquisition opportunities to provide funds
.
The company is a global biomedical company in the commercialization stage, focusing on the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immune diseases
.
In addition, the listing of the unprofitable company Connoa Biotechnology has been favored by many capitals
.
On July 8, Connoa Bio was listed on the Hong Kong Stock Exchange, sponsored by Morgan Stanley, CICC, and Huatai International
.
Cornerstone investors, including Temasek, Hillhouse Capital, UBS and Invesco Asset Management (Singapore) Limited
.
The funds raised in this round amounted to HK$3.
571 billion, which will be used for the development and commercialization of key candidate pipelines
.
The company focuses on the development of innovative biological therapies in the field of autoimmunity and tumor immunotherapy
.
From the perspective of the industry, behind the continuous entry of capital is the strong rise of China's innovative biotechnology industry
.
In recent years, in the face of the growing domestic market, with the support of favorable policies and the increasing acceptance of innovative therapies in the country, a number of local biotechnology companies have risen rapidly, constantly developing innovative drugs, and are facing a huge scale.
, While focusing more and more on innovation in the domestic market, it also faces the international market
.
In this context, China's biotechnology has gradually attracted a wider range of strategic investors
.
However, the industry also pointed out that there are still parts to be solved and developed, including basic research and technology transfer, which need to be improved
.
